Linklaters, Goodwin Steer Bayer's $425M Women's Health Bet
Bayer, led by Linklaters, said Tuesday it will pay $425 million upfront and up to $875 million total to acquire Goodwin Procter-guided KaNDy Therapeutics, a clinical-stage biotechnology company focused on women's...To view the full article, register now.
Already a subscriber? Click here to view full article